Published:
Psilocybe Cyanescens
"Wavy Cap, Blue Halos"
![[object Object]](https://d16q8n2b2c01ef.cloudfront.net/media/PsilocybeCyanescens-1_new-800x450.webp)
Scientific Classification
About
Psilocybe cyanescens, known commonly as the Wavy Cap, is a potent psychedelic mushroom recognized by its undulating cap edges and strong bluing reaction when bruised. Native to temperate regions, especially the Pacific Northwest of the United States and parts of Europe, it is rich in psilocybin and psilocin, the compounds responsible for its hallucinogenic effects.
History
First described in the mid-20th century, P. cyanescens gained popularity during the psychedelic movement of the 1960s and has since become one of the most widely known wild psilocybin species. It thrives in woodchip mulch and landscaped areas, often appearing in urban settings during the fall.
Historically, it has not been used in indigenous rituals like some other Psilocybe species, but modern psychonauts have embraced it for its strong visuals, intense introspective journeys, and potential therapeutic applications.
Overview
The mushroom typically has a caramel-colored cap, 1.5–5 cm wide, with a characteristic wavy margin as it matures. Its gills are closely spaced, turning from pale to dark purple-brown as spores develop. The stem is slender and whitish, bruising deep blue when damaged—a key indicator of psilocybin presence.
Due to its potency, even small amounts can produce profound effects, including visual distortions, altered perception of time, and emotional or spiritual experiences. It is illegal in many regions, but continues to be studied for potential use in treating mental health conditions like depression and PTSD.
Physical Characteristics
Caps:
Medium-sized with a convex shape, initially caramel-brown and becoming light brown with age, sometimes with a wavy edge
Gills:
Initially pale yellow, maturing to dark brown
Psychoactive Effects
Hallucinogenic
Users may experience changes in visual perception such as enhanced colors, geometric patterns, or distortions.
Euphoric
Users often report intense feelings of joy and happiness
Pharmacology
Helps With
Depression
Psilocybin has been shown to have antidepressant effects in clinical trials.
Anxiety
Psilocybin has been shown to have anxiolytic effects in clinical trials.
Addiction
Psilocybin has been shown to have anti-addictive effects in clinical trials.
PTSD
Psilocybin has been shown to have treat PTSD in clinical trials.
ADD ADHD
Psilocybin has been shown to improve attention and focus in clinical trials.
OCD
Psilocybin has been shown to reduce OCD symptoms in clinical trials.
Pain
Microdosing psilocybin has been shown to help with certain types of pain
Migraines
Research shows that psilocybin, the active compound in magic mushrooms, has potential therapeutic benefits for migraines.4 A small-scale study conducted by Yale School of Medicine found that a single dose of psilocybin reduced the likelihood of having a migraine attack in two weeks.
Possible Side Effects
Nausea
Can cause stomach discomfort and nausea, especially when eaten raw.
Grow at Home
Start your cultivation journey with quality grow kits from verified vendors
Chemical Constituents
Medicinal Chemistry
Similar Species
![[object Object]](https://d16q8n2b2c01ef.cloudfront.net/media/PsilocybeSemilanceata_new-400x400.webp)
Species: Psilocybe semilanceata
Edibility: Psychoactive
Key Differences: Psilocybe semilanceata has a more conical or bell-shaped cap and does not bruise blue as readily as Psilocybe cyanescens.
![[object Object]](https://d16q8n2b2c01ef.cloudfront.net/media/PsilocybeSemilanceata_new-400x400.webp)
Species: Psilocybe semilanceata
Edibility: Psychoactive
Mushroom Ratings
4.0
(1)
Based on 1 Review
5
★4
★3
★2
★1
★Share your thoughts
If you've consumed this mushroom, share your thoughts with our community
01/29/2025
Anonymous
References
- Sekssaoui, M. (2024). Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?. .
- Ley, L. (2023). Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. .
- Bae, S. (2023). Cardiac Arrest Associated With Psilocybin Use and Hereditary Hemochromatosis. .
- Schindler, E. (2022 ). Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial. .
- Barrett, F. (2022). Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation. .
- Desai, S. (2022). Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Users—A National Survey Study. .
- Rucker, J. (2021). Psilocybin: From Serendipity to Credibility?. .
- Schindler, E. (2021). Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. .
- Raval, N. (2021). A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain. .
- Kuypers, K. (2019). Psychedelic medicine: The biology underlying the persisting psychedelic effects. .